DCM
LCTX icon

DAFNA Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

DAFNA Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,511,374
Closed -$1.13M – 78
2025
Q1 		$1.13M Hold
2,511,374
– – 0.32% 52
2024
Q4 		$1.26M Buy
2,511,374
+1,160,666
+86% +$852K 0.32% 53
2024
Q3 		$1.22M Hold
1,350,708
– – 0.29% 58
2024
Q2 		$1.35M Sell
1,350,708
-15,600
-1% -$17.2K 0.32% 54
2024
Q1 		$2.02M Buy
+1,366,308
New +$1.55M 0.46% 45
2023
Q3 		– Sell
-140,000
Closed -$197K – 76
2023
Q2 		$197K Hold
140,000
– – 0.05% 71
2023
Q1 		$210K Hold
140,000
– – 0.06% 68
2022
Q4 		$164K Hold
140,000
– – 0.05% 76
2022
Q3 		$158K Hold
140,000
– – 0.04% 84
2022
Q2 		$221K Hold
140,000
– – 0.06% 86
2022
Q1 		$216K Buy
140,000
+60,000
+75% +$93.1K 0.06% 90
2021
Q4 		$196K Buy
+80,000
New +$187K 0.05% 87
2021
Q2 		– Sell
-75,400
Closed -$177K – 89
2021
Q1 		$177K Sell
75,400
-4,600
-6% -$11K 0.04% 87
2020
Q4 		$141K Sell
80,000
-15,000
-16% -$21K 0.04% 74
2020
Q3 		$89K Hold
95,000
– – 0.03% 79
2020
Q2 		$83K Hold
95,000
– – 0.02% 86
2020
Q1 		$79K Hold
95,000
– – 0.03% 79
2019
Q4 		$85K Hold
95,000
– – 0.03% 80
2019
Q3 		$93K Hold
95,000
– – 0.04% 86
2019
Q2 		$105K Hold
95,000
– – 0.04% 82
2019
Q1 		$124K Sell
95,000
-5,000
-5% -$6.22K 0.05% 76
2018
Q4 		$91K Sell
100,000
-14,300
-13% -$21.9K 0.05% 79
2018
Q3 		$235K Sell
114,300
-93,269
-45% -$196K 0.1% 71
2018
Q2 		$374K Hold
207,569
– – 0.18% 64
2018
Q1 		$489K Sell
207,569
-106,756
-34% -$250K 0.24% 60
2017
Q4 		$591K Buy
+314,325
New +$686K 0.32% 58

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

DAFNA Capital Management's LCTX Position: Q2 2025 in Review

DAFNA Capital Management sold out of Lineage Cell Therapeutics (LCTX) in Q2 2025, closing a stake of 2,511,374 shares — an estimated $1.13M sold.

DAFNA Capital Management first reported a position in LCTX in Q4 2017 and held it in 26 quarters. The position peaked at $2.02M in Q1 2024. 129 funds tracked by Wall St. Rank hold LCTX as of Q2 2025.

  • DAFNA Capital Management reported no remaining Lineage Cell Therapeutics position as of Q2 2025 after selling out during the quarter.
  • DAFNA Capital Management sold 2,511,374 Lineage Cell Therapeutics shares in Q2 2025, an estimated $1.13M.
  • DAFNA Capital Management first reported a position in Lineage Cell Therapeutics in Q4 2017 and held it in 26 quarters.
  • DAFNA Capital Management's Lineage Cell Therapeutics position peaked at $2.02M in Q1 2024.
  • 129 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2025.

Based on DAFNA Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.